{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045054","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.627048+00:00","generated_at":"2026-05-30T05:47:23.192650+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CMS denies Caldolor separate Medicare reimbursement under NOPAIN Act for CY2025","bullets":["CMS excluded Caldolor from NOPAIN Act separate payment list announced Nov 1, 2024 for CY2025.","CMS concluded Caldolor does not qualify because FDA indication lacks mention of post-operative use.","Company submitted comments in July 2023 and July 2024 arguing Caldolor meets statutory requirements.","Company says majority of Caldolor use is surgical and FDA approval based on post-surgical pain studies.","Cumberland is evaluating options; calls CMS determination inconsistent with NOPAIN Act intent."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045054","json":"https://secwatch.observer/filing/0001628280-24-045054.json","markdown":"https://secwatch.observer/filing/0001628280-24-045054.md","text":"https://secwatch.observer/filing/0001628280-24-045054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024045054/0001628280-24-045054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024045054/cpix-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:47:23.192650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}